Skip to main content

Articles By Aurelie Najm, MD, PhD

JAK Janus

JAK/STAT pathway in pyoderma gangrenosum: a new therapeutic highway?

By Aurelie Najm, MD, PhD
16 June 2022

Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases. 

Read Article
Gender

Time to consider gender stratification in AxSpA diagnosis and management

By Aurelie Najm, MD, PhD
07 June 2022

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked.

Read Article
Feet, foot

Pre-clinical RA: starting off the wrong foot

By Aurelie Najm, MD, PhD
09 December 2021

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

By Aurelie Najm, MD, PhD
03 December 2021

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
SI AS SpA ACR

TNF inhibitors and radiographic progression in axSpA

By Aurelie Najm, MD, PhD
07 November 2021

A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.

Read Article
Feet, foot

Pre-clinical RA: starting off the wrong foot

By Aurelie Najm, MD, PhD
06 November 2021

Patients with clinically suspect arthralgia can represent a challenge for clinicians, in a sense that there are not yet reliable markers to predict evolution to clinical RA nor enough evidence to support routine prescription of conventional synthetic DMARDS or biologic treatments in this setting.

Read Article
joint.wrist_.pain_.CTS_.Carpal.jpg

RA after 70: Too Old for bioDMARDs?

By Aurelie Najm, MD, PhD
07 June 2021

In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.

Read Article
lung%2Cbright.jpg

New insights in RA-ILD therapeutics

By Aurelie Najm, MD, PhD
04 June 2021

RA associated ILD (RA-ILD) is the most common extra-articular manifestation in RA. Its prevalence varies considerably, ranging from 5% to 30%, and is often underestimated since patients only become symptomatic or display abnormalities on chest X-Ray at a late stage of disease, leading to subsequent delay in diagnosis. In this context, several groups advocate for an earlier and more precise detection, using high resolution chest computed tomography (HRCT), which is the most sensitive for pre-clinical RA-ILD diagnosis. But why would we want to diagnose early a manifestation that we cannot treat?

Read Article
×